ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced the use of their technology to create a long-acting semaglutide that can be administered once monthly. The ProLynx...

Exavir Therapeutics announces publication of preclinical data for ultra-long-acting dolutegravir prodrug XVIR-120 Ultra-long-acting plasma pharmacokinetics and biodistribution to tissues of interest demonstrated in three species Injections were well tolerated with no adverse findings in preliminary toxicology...